David Michael Padilla

US Patent:

20190262469, Aug 29, 2019

Filed:

Sep 2, 2016

Appl. No.:

15/757254

Inventors:

C. Jeffrey Brinker - Albuquerque NM, US
Eric C. Carnes - Albuquerque NM, US
Carlee Erin Ashley - Albuquerque NM, US
Oscar Negrete - Pleasanton CA, US
Dan C Wilkinson - Los Angeles CA, US
Brian S Wilkinson - Albuquerque NM, US
David Patrick Padilla - Albuquerque NM, US

International Classification:

A61K 47/69
A61K 31/337
A61P 31/04

Abstract:

The present disclosure relates to protocells that are useful in the treatment and prevention of viral infections, including but not limited to infections caused by a Hendra virus and Nipah virus (NiV). The present disclosure relates to protocells that are useful in the treatment of bacterial infections, including antibiotic-resistant bacterial infections. The protocells are coated with a lipid bi- or multilayer comprising at least one moiety that targets a viral cellular receptor and at least one moiety that ruptures a virally-infected cell membrane. The present disclosure further relates to novel mesoporous metal oxide nanoparticles and related protocells that are useful in the treatment and/or prevention of a wide variety of disorders, including a cancer or a bacterial or viral infection. Such nanoparticles and protocells can be functionalized to allow for synergistic loading of a wide variety of active ingredients.

US Patent:

20170232115, Aug 17, 2017

Filed:

Dec 15, 2016

Appl. No.:

15/380962

Inventors:

- Albuquerque NM, US
Eric C. Carnes - Albuquerque NM, US
Mohammed Houman Fekrazad - Albuquerque MN, US
Linda A. Felton - Albuquerque NM, US
Oscar Negrete - Pleasanton CA, US
David Patrick Padilla - Albuquerque NM, US
Brian S. Wilkinson - Albuquerque NM, US
Dan C. Wilkinson - Los Angeles CA, US
Cheryl L. Willman - Albuquerque NM, US

International Classification:

A61K 49/00
A61K 33/24
A61K 31/513
C12N 15/113
A61K 38/45
A61K 31/506
A61K 38/47
A61K 31/465
A61K 31/192
A61K 31/704
A61K 48/00

Abstract:

The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

US Patent:

20150272885, Oct 1, 2015

Filed:

Oct 12, 2012

Appl. No.:

14/350674

Inventors:

- Albuquerque NM, US
Eric C. Carnes - Albuquerque NM, US
Mohammad Houman Fekrazad - Albuquerque NM, US
Linda A. Felton - Albuquerque NM, US
Oscar Negrete - Pleasanton CA, US
David Patrick Padilla - Albuquerque NM, US
Brian S. Wilkinson - Albuquerque NM, US
Dan C. Wilkinson - Albuquerque NM, US
Cheryl L. Willman - Albuquerque NM, US

International Classification:

A61K 9/127
A61K 45/06
A61K 31/704
A61K 31/513
A61K 31/713
A61K 38/17

Abstract:

The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.